Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 19:12:708247.
doi: 10.3389/fendo.2021.708247. eCollection 2021.

Dual Trigger for Final Follicular Maturation Improves Cumulative Live-Birth Rate in Ovarian Stimulation for Freeze-All In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles

Haiyan Zhu  1   2 , Chenqiong Zhao  1   2 , Yibin Pan  1   2 , Hanjing Zhou  1   2 , Xiaoying Jin  1   2 , Wen Xu  1   2 , Songying Zhang  1   2
Affiliations

Dual Trigger for Final Follicular Maturation Improves Cumulative Live-Birth Rate in Ovarian Stimulation for Freeze-All In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles

Haiyan Zhu et al. Front Endocrinol (Lausanne). .

Abstract

Study question: Does dual trigger in freeze-all in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles improve the cumulative live-birth outcome compared with human chorionic gonadotropin (hCG) trigger?

Summary answer: Dual trigger for final follicular maturation improves the cumulative pregnancy and live-birth rates compared with hCG trigger in freeze-all IVF/ICSI cycles.

What is known already: Dual trigger could increase the numbers of oocytes and mature oocytes and improve pregnancy rates.

Study design size duration: This retrospective cohort analysis included data from 4438 freeze-all IVF/ICSI cycles between January 2012 and December 2017.

Participants/materials setting methods: Women aged 20-49 years who underwent ovarian stimulation and oocyte retrieval for autologous IVF/ICSI with a freeze-all policy in our centre were enrolled. Data on number of oocytes retrieved, number of mature oocytes, clinical pregnancy rate, live-birth rate, cumulative pregnancy rate, and cumulative live-birth rate (CLBR) were assessed and compared between patients who underwent a dual trigger and hCG trigger. Multivariate logistic regression was performed to identify and adjust for factors known to independently affect the CLBR.

Main results and the role of chance: A total of 4438 IVF/ICSI cycles were analyzed, including 1445 cycles with single hCG trigger and 2993 cycles with dual trigger. The cumulative biochemical pregnancy rate (60.8% vs. 68.1%, P<0.001; odds ratio (OR): 0.727; 95% confidence interval (CI): 0.638-0.828), cumulative clinical pregnancy rate (52.9% vs. 58.5%, P<0.001; OR: 0.796; 95%CI: 0.701-0.903), and CLBR (44.3% vs. 50.5%, P<0.001; OR: 0.781; 95%CI: 0.688-10.886) were all significantly lower in the hCG-trigger group compared with the dual-trigger group. The clinical pregnancy rate (48.2% vs. 58.2%, P=0.002; OR: 0.829; 95%CI: 0.737-0.934) and embryo implantation rate (34.4% vs. 38.9%, P<0.001; OR: 0.823; 95%CI: 0.750-0.903) in each transfer cycle were also significantly lower in the hCG-trigger group compared with the dual-trigger group. After controlling for all potential confounding variables, the trigger method was identified as an independent factor affecting the CLBR. The OR and 95%CI for hCG trigger were 0.780 and 0.641-0.949 (P=0.013).

Limitations reasons for caution: The data used to analyse the effect of dual trigger on cumulative pregnancy and live-birth outcomes were retrospective, and the results may thus have been subject to inherent biases. Further prospective randomized controlled trials are required to verify the beneficial effects of dual trigger.

Wider implications of the findings: Dual trigger had a positive effect on CLBRs, suggesting that it could be used as a routine trigger method in freeze-all cycles.

Study funding/competing interests: This study was supported by grants from National Key Research and Development Program of China (2018YFC1004800), the Natural Science Program of Zhejiang (LY19H040009), the National Natural Science Foundation of China (No. 81601236). No authors have competing interests to declare.

Keywords: cumulative live birth; dual trigger; freeze-all; hCG; in vitro fertilization.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Haas J, Bassil R, Samara N, Zilberberg E, Mehta C, Orvieto R, et al. . GnRH Agonist and hCG (Dual Trigger) Versus hCG Trigger for Final Follicular Maturation: A Double-Blinded, Randomized Controlled Study. Hum Reprod (2020) 35(7):1648–54. 10.1093/humrep/deaa107 - DOI - PubMed
    1. Engmann L, Benadiva C, Humaidan P. GnRH Agonist Trigger for the Induction of Oocyte Maturation in GnRH Antagonist IVF Cycles: A SWOT Analysis. Reprod Biomed Online (2016) 32(3):274–85. 10.1016/j.rbmo.2015.12.007 - DOI - PubMed
    1. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, et al. . GnRHa Trigger and Individualized Luteal Phase hCG Support According to Ovarian Response to Stimulation: Two Prospective Randomized Controlled Multi-Centre Studies in IVF Patients. Hum Reprod (2013) 28(9):2511–21. 10.1093/humrep/det249 - DOI - PubMed
    1. O’Neill KE, Senapati S, Maina I, Gracia C, Dokras A. GnRH Agonist With Low-Dose hCG (Dual Trigger) Is Associated With Higher Risk of Severe Ovarian Hyperstimulation Syndrome Compared to GnRH Agonist Alone. J Assist Reprod Genet (2016) 33(9):1175–84. 10.1007/s10815-016-0755-8 - DOI - PMC - PubMed
    1. Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A. Targeting the Vascular Endothelial Growth Factor System to Prevent Ovarian Hyperstimulation Syndrome. Hum Reprod Update (2008) 14(4):321–33. 10.1093/humupd/dmn008 - DOI - PubMed

Publication types

Substances